Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Forns X
- Didier S
- Mutimer D
- Fagiuoli S
- Navasa M
- Agarwal K
- Colombo M
- Herzer K
- Nevens F
- Daems B
- Janssen K
- Ouwerkerk-Mahadevan S
- Kimko H
- Lathouwers E
- Witek J
- Van Solingen-Ristea R
Grupos
Abstract
Background and rationale. The REPLACE study (NCT01571583) investigated telaprevir-based triple therapy in patients who have recurrent genotype 1 hepatitis C virus (HCV) infection following liver transplantation and are on a stable immunosuppressant regimen of tacrolimus or cyclosporin A. Patients received telaprevir 750 mg 8-hourly with pegylated interferon 180 mu g weekly and ribavirin 600 mg daily, followed by a further 36 weeks of pegylated interferon and ribavirin alone and 24 weeks of follow-up. Efficacy (sustained virological response [SVR] 12 weeks after last planned study dose), safety and tolerability of telaprevir throughout the study were assessed. Pharmacokinetics of telaprevir, tacrolimus and cyclosporin A were also examined. Results: In total, 74 patients were recruited. Overall, 72% (53/74; 95% CI: 59.9 to 81.5) of patients achieved SVR at 12 weeks following completion of treatment. Anticipated increases in plasma concentrations of tacrolimus and cyclosporin A occurred during telaprevir treatment and were successfully managed through immunosuppressant dose reduction and, for tacrolimus, reduced dosing frequency. Safety and tolerability of telaprevir-based triple therapy were generally comparable with previous data in non-transplant patients, although rates of reported anemia (55% [41/74]) were higher. Elevated plasma creatinine (46% [34/74]) was observed during REPLACE - consistent with the post-liver transplant population and the co-administered immunosuppressants. Conclusion: Telaprevir-based triple therapy in patients with recurrent genotype 1 HCV infection following liver transplantation produced high rates of SVR. Therapeutic concentrations of immunosuppressants were maintained successfully through dose modification during telaprevir treatment.
Datos de la publicación
- ISSN/ISSNe:
- 1665-2681, 1665-2681
- Tipo:
- Article
- Páginas:
- 512-523
- PubMed:
- 27236150
- Factor de Impacto:
- 0,679 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Annals of Hepatology ELSEVIER ESPANA
Citas Recibidas en Web of Science: 5
Documentos
- No hay documentos
Métricas
Filiaciones
Keywords
- Telaprevir; Hepatitis C infection; Liver transplant
Campos de Estudio
Cita
Forns X,Didier S,Mutimer D,Fagiuoli S,Navasa M,Agarwal K,BERENGUER M,Colombo M,Herzer K,Nevens F,Daems B,Janssen K,Ouwerkerk S,Kimko H,Lathouwers E,Witek J,Van Solingen R. Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. Ann. Hepatol. 2016. 15. (4):p. 512-523. IF:1,678. (4).
Portal de investigación